Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

669 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study.
Chan JK, Tian C, Kesterson JP, Lin KY, Darcy K, Richardson MT, Kapp DS, Monk BJ, McNally L, Landrum L, Copeland L, Walker JL, Wenham RM, Phippen N, Spirtos NM, Tewari K, Shahin M, Berry L, Bell JG. Chan JK, et al. Among authors: copeland l. Gynecol Oncol. 2024 Feb;181:54-59. doi: 10.1016/j.ygyno.2023.12.009. Epub 2023 Dec 21. Gynecol Oncol. 2024. PMID: 38134754 Clinical Trial.
Endometrial cancer state of the science meeting.
Kitchener HC, Trimble EL; Endometrial Cancer Working Group of the Gynecologic Cancer Intergroup. Kitchener HC, et al. Int J Gynecol Cancer. 2009 Jan;19(1):134-40. doi: 10.1111/IGC.0b013e3181995f90. Int J Gynecol Cancer. 2009. PMID: 19258955
Development and validation of the Michigan Chronic Disease Simulation Model (MICROSIM).
Burke JF, Copeland LL, Sussman JB, Hayward RA, Gross AL, Briceño EM, Whitney R, Giordani BJ, Elkind MSV, Manly JJ, Gottesman RF, Gaskin DJ, Sidney S, Yaffe K, Sacco RL, Heckbert SR, Hughes TM, Galecki AT, Levine DA. Burke JF, et al. Among authors: copeland ll. PLoS One. 2024 May 16;19(5):e0300005. doi: 10.1371/journal.pone.0300005. eCollection 2024. PLoS One. 2024. PMID: 38753617 Free PMC article.
Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Levine MD, Wang H, Sriram B, Khan A, Senter L, McLaughlin EM, Bixel KL, Chambers LM, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Backes FJ. Levine MD, et al. Among authors: copeland lj. Gynecol Oncol. 2024 Mar;182:51-56. doi: 10.1016/j.ygyno.2023.12.008. Epub 2024 Jan 22. Gynecol Oncol. 2024. PMID: 38262238
669 results